Home » Posts tagged 'VLG'

Tag Archives: VLG

Alan Green talks Venture Life Group #VLG, Hemogenyx #HEMO & Gfinity #GFIN on Vox Markets podcast

Alan Green discusses Venture Life Group #VLG, Hemogenyx #HMO & Gfinity #GFIN with Justin Waite on the Vox Markets podcast. Interview is 13 mins in

Venture Life Group #VLG publishes trading update & reports FY profits ahead of market expectations

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces its unaudited trading update for the year ended 31st December 2020, ahead of the announcement of the Group’s audited results on 25th March 2021.

The Company expects to report revenues for the year ended 31st December 2020 of £30.1 million, 49% higher than for 2019, and adjusted* EBITDA is expected to be not less than £6 million, more than double the 2019 adjusted EBITDA. There were no further shipments of product to our Chinese oral care partner in H2, but shipments are due to resume in H1 2021.

Despite the challenges presented by the COVID-19 pandemic, revenues across the business grew significantly in 2020, notably in sales of the VLG Brands, which now represent 50% of revenues, compared to 33% in 2019. The significantly increased revenues and higher prevalence of revenues from the VLG Brands in the year have contributed to improving gross margin, as expected. Revenues from the newly acquired PharmaSource business were ahead of 2019, and a number of planned synergies have already been achieved.

The clinical study at Cardiff University on our mouthwashes is still on-going and we will update the market when the results have been published in due course.

Jerry Randall, CEO of Venture Life, commented: “I am delighted to update the market on the delivery of strong growth during 2020. It has been a particularly challenging year for everyone, but the team at Venture Life performed exceptionally well to ensure that the business continued to operate and meet customer requirements. The placing and open offer completed in December 2020 has given us substantial funds, leaving us with net cash (excluding finance lease liabilities) of £35.5m as at the year end,  with which we can now pursue our ambitious acquisition growth and, with an order book ahead of the same time last year, I look forward to updating the market further as we go through the year. “

*Adjusted EBITDA is EBITDA before deduction of exceptional items and share based payments

This announcement contains price sensitive information.

For further information, please contact:

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Cenkos Securities plc (Nomad and Joint Broker)

+44 (0) 20 7397 8900

Michael Johnson / Russell Kerr (Sales)

Stephen Keys / Camilla Hume (Corporate Finance)

N+1 Singer (Joint Broker)

+44 (0) 20 7496 3000

Jonathan Dighe (Sales)

Shaun Dobson / Carlo Spingardi (Corporate Finance)

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group’s product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women’s intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group’s international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

Alan Green talks Versarien #VRS, Venture Life Group #VLG & Bidstack #BIDS on Vox Markets podcast

Alan Green discusses Versarien #VRS, Venture Life Group #VLG & Bidstack #BIDS with Justin Waite on the Vox Markets podcast. Interview is 8 minutes 38 seconds in.

Alan Green presents the investment case for Katoro Gold #KAT and Venture Life Group #VLG on his weekly Stockbox Media Research talk

Alan Green presents the investment case for Katoro Gold #KAT and Venture Life Group #VLG on his weekly Stockbox Media Research talk

Alan Green talks markets, Power Metal Resources #POW, Itaconix #ITX & Venture Life Grp #VLG on the UK Investor Magazine podcast

FTSE 100: The influences of vaccines and Brexit on London’s leading index

Alan Green talks markets, Power Metal Resources #POW, Itaconix #ITX & Venture Life Grp #VLG with Jonathan Roy on the UK Investor Magazine podcast

Alan Green presents the investment case for Synairgen #SNG, Omega Diagnostics #ODX, Open Orphan #ORPH & Venture Life #VLG on his weekly Stockbox Media Research talk

Alan Green presents the investment case for Synairgen #SNG, Omega Diagnostics #ODX, Open Orphan #ORPH & Venture Life #VLG on his weekly Stockbox Media Research talk.

Alan Green talks to Venture Life Group #VLG CCO Sharon Collins about the results of the groundbreaking COVID Mouthwash trial at Cardiff University.

Alan Green talks to Venture Life Group (AIM: VLG) CCO Sharon Collins about the results of the groundbreaking COVID Mouthwash trial at Cardiff University. Sharon also discusses the group progress to date in 2020, and summarises the current investment proposition for investors

Alan Green talks Venture Life Group #VLG, RA International #RAI & Arkle Resources #ARK on Vox Markets podcast

Alan Green discusses Venture Life Group #VLG, RA International #RAI & Arkle Resources #ARK on Vox Markets podcast. Interview is 14 minutes 45 seconds in.

Alan Green discusses Venture Life #VLG, Catenae Innovation #CTEA, British Honey #BHC & OnTheMarket #OTMP on Vox Markets podcast

Alan Green discusses Venture Life #VLG, Catenae Innovation #CTEA, British Honey #BHC & OnTheMarket #OTMP with Justin Waite on the Vox Markets podcast. Interview is 28 minutes in.

Venture Life Group #VLG – CEO Jerry Randall discusses today’s interim results & trading update

Alan Green talks to Venture Life Group (VLG) CEO Jerry Randall about the company’s interim results.

Jerry goes through the numbers and commercial developments for the period, before discussing post period-end developments, including an independent study at Cardiff University on the effects on Dentyl Dual Action mouthwash on patients affected by COVID-19.

Jerry explains the resilience and adaptability of the Venture Life business model in countering the challenge of the COVID lockdown, and highlights how the group’s strong cash position will fund any future acquisitions.

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.